Benzindopyrine belongs to anticholinergic agents. It was studied as an antipsychotic drug.

FENYRIPOL is a skeletal muscle relaxant.

MSDC 0602, a first-in-class oral, once-daily, insulin sensitiser that acts by stimulating mitochondrial proteins, is being developed by Metabolic Solutions and Cirius Therapeutics for treatment Type 2 diabetes mellitus and Non-alcoholic steatohepatitis. MSDC-0602 prevented and reversed liver fibrosis and suppressed expression of markers of stellate cell activation in livers of mice fed a diet rich in trans-fatty acids, fructose, and cholesterol. Moreover, mice with liver-specific deletion of MPC2 were protected from development of NASH on this diet. MSDC-0602 directly reduced hepatic stellate cell activation in vitro, and MSDC-0602 treatment or hepatocyte MPC2 deletion also limited stellate cell activation indirectly by affecting secretion of exosomes from hepatocytes. Cirius Therapeutics plans the phase III trial for Type 2 diabetes mellitus and Non-alcoholic steatohepatitis in September 2019

Mebenoside is an anti-inflammatory agent.

Halonamine was studied as an antiparkinsonian agent.

Tropapride is dopamine D2 receptor antagonist, which potential high antipsychotic activity has been clearly shown in biochemical and pharmacological tests.

Masilukast (ZD 3523) is an antagonist of leukotriene D4 (LTD4). It opposes LTD4-induced bronchoconstriction. It was being developed for the treatment of asthma.

Hexacyprone has been used as a choleretic agent. Information about the current use of this compound is not available.

Japan Tobacco developed JTV-519 (known also as K201) as an antiarrhythmic agent. This drug was in Phase II trials for the potential treatment of Atrial Fibrillation, but study was terminated. In experimental myofibrillar overcontraction models, JTV-519 demonstrated greater cardioprotectant effects than propranolol, also, this drug investigated against heart failure, but then these researches have been discontinued. In addition, K201 was in phase II clinical trial for investigation its topical implementation for Atopic Dermatitis. The mechanism of its action is both complex and controversial, known that it is a non-specific blocker of sodium, potassium and calcium channels (multiple-channel blocker). It is believed to stabilize the closed state of the RyR2 (cardiac ryanodine receptor) by increasing its affinity for the FKBP12.6 (12.6 kDa FK506 binding protein), in addition was suggested, that suppression of spontaneous Ca2 release and the activity of RyR2 contributes, at least in part, to the anti-arrhythmic properties of K201.

Dioxethedrin is the ephedrine derivative. It is the beta-adrenergic agonist. As a bronchodilator and sympathomimetic agent is was used in antitussive syrup Bexol.